Thyroid function interpretation is the systematic analysis of thyroid-stimulating hormone (TSH), free thyroxine (FT4), and free triiodothyronine (FT3) levels to classify thyroid status and guide clinical management. The thyroid gland produces thyroxine (T4) and triiodothyronine (T3), which regulate metabolism, cardiovascular function, bone density, neurological development, and nearly every organ system in the body. TSH, secreted by the pituitary gland in response to signals from the hypothalamus, is the primary regulatory signal — when thyroid hormone levels fall, TSH rises to stimulate more production, and vice versa. This negative feedback loop means TSH is the most sensitive indicator of thyroid status. The five principal patterns of thyroid dysfunction are: overt hypothyroidism (high TSH, low FT4 — insufficient thyroid hormone production requiring treatment); subclinical hypothyroidism (high TSH, normal FT4 — early or compensated dysfunction); overt hyperthyroidism (low TSH, high FT4 or FT3 — excess thyroid hormone from Graves disease, toxic adenoma, or toxic multinodular goitre); subclinical hyperthyroidism (low TSH, normal FT4 and FT3 — risk of atrial fibrillation and osteoporosis); and central (secondary) hypothyroidism (low TSH, low FT4 — pituitary or hypothalamic failure). Accurate interpretation requires knowledge of assay reference ranges, clinical context, and confounding factors such as illness, medications, and pregnancy.
Interpretation grid: TSH high + FT4 low = Overt hypothyroidism; TSH high + FT4 normal = Subclinical hypothyroidism; TSH low + FT4/FT3 high = Overt hyperthyroidism; TSH low + FT4/FT3 normal = Subclinical hyperthyroidism; TSH low/normal + FT4 low = Central hypothyroidism
- 1Measure TSH first — it is the most sensitive screening test for thyroid dysfunction. Normal TSH (0.4-4.0 mU/L in most labs) makes significant thyroid disease unlikely.
- 2If TSH is abnormal, measure FT4 (and FT3 if TSH is suppressed) to differentiate subclinical from overt disease and identify the pattern.
- 3Classify the pattern: high TSH + low FT4 = overt hypothyroidism; high TSH + normal FT4 = subclinical hypothyroidism; low TSH + high FT4/FT3 = overt hyperthyroidism; low TSH + normal FT4/FT3 = subclinical hyperthyroidism; low-normal TSH + low FT4 = central hypothyroidism.
- 4Order thyroid antibodies (anti-TPO, anti-TSH receptor) where appropriate to determine aetiology.
- 5Consider confounders: illness lowers TSH and FT4 non-specifically (sick euthyroid syndrome); biotin supplementation can falsely lower TSH and elevate FT4 in immunoassays; amiodarone raises T4 and may raise TSH or cause either hypo or hyperthyroidism.
- 6Apply clinical context: symptoms, goitre, exophthalmos, cardiac status, and pregnancy all modify the significance and urgency of abnormal results.
- 7Treat or refer according to the pattern identified, monitoring TSH 6-8 weeks after any dose change in levothyroxine.
Levothyroxine replacement required
Very high TSH combined with subnormal FT4 confirms overt hypothyroidism. Positive anti-TPO antibodies indicate Hashimoto thyroiditis as the underlying cause. Levothyroxine replacement is indicated, starting at 1.6 mcg/kg/day in young healthy adults.
Treatment decision depends on TSH level, symptoms, age, and antibody status
TSH is elevated but FT4 remains within the normal range — subclinical hypothyroidism. Treatment is generally recommended when TSH exceeds 10 mU/L, in symptomatic patients, in pregnancy, or in anti-TPO positive patients at higher progression risk.
Antithyroid drugs (carbimazole/methimazole), radioiodine, or surgery
Suppressed TSH with markedly elevated FT4 and FT3, combined with positive TRAb, is diagnostic of Graves disease. Treatment options include antithyroid drugs for block-replace or titration regimens, radioactive iodine, or thyroidectomy.
TSH cannot rise normally due to pituitary failure — FT4 guides diagnosis
In central hypothyroidism, TSH may appear falsely normal or even mildly low because the pituitary cannot secrete TSH appropriately in response to low FT4. This is a critical trap: a 'normal' TSH in a patient with pituitary disease does not exclude hypothyroidism. FT4 must always be measured in this context.
Diagnosing and monitoring hypothyroidism in primary care, guiding levothyroxine dosing, representing an important application area for the Thyroid Function in professional and analytical contexts where accurate thyroid function calculations directly support informed decision-making, strategic planning, and performance optimization
Identifying hyperthyroidism aetiology (Graves disease vs toxic nodule) to guide treatment selection, representing an important application area for the Thyroid Function in professional and analytical contexts where accurate thyroid function calculations directly support informed decision-making, strategic planning, and performance optimization
Thyroid screening in pregnant women to prevent fetal neurodevelopmental impairment from maternal hypothyroidism, representing an important application area for the Thyroid Function in professional and analytical contexts where accurate thyroid function calculations directly support informed decision-making, strategic planning, and performance optimization
Monitoring thyroid function in patients on amiodarone, lithium, or immune checkpoint inhibitor therapy, representing an important application area for the Thyroid Function in professional and analytical contexts where accurate thyroid function calculations directly support informed decision-making, strategic planning, and performance optimization
Post-thyroidectomy and post-radioactive iodine monitoring to ensure adequate replacement or TSH suppression in differentiated thyroid cancer, representing an important application area for the Thyroid Function in professional and analytical contexts where accurate thyroid function calculations directly support informed decision-making, strategic planning, and performance optimization
Amiodarone-related thyroid dysfunction
{'title': 'Amiodarone-related thyroid dysfunction', 'body': 'Amiodarone contains 37% iodine by weight and can cause both hypothyroidism (type 1 and 2 amiodarone-induced hyperthyroidism — AIH) and hypothyroidism. Amiodarone also raises FT4 levels and lowers T3 conversion even in euthyroid patients, making interpretation complex. Baseline and 6-monthly thyroid monitoring is essential for all patients on amiodarone.'}
Thyroid disease in pregnancy
{'title': 'Thyroid disease in pregnancy', 'body': 'Untreated overt hypothyroidism in pregnancy carries risks of miscarriage, preeclampsia, placental abruption, and impaired fetal neurodevelopment. Gestational TSH reference ranges differ by trimester. Subclinical hypothyroidism in pregnancy is actively debated but many guidelines recommend treatment when TSH exceeds 2.5 mU/L in the first trimester, particularly in anti-TPO positive women.'}
Extremely large or small input values in the Thyroid Function may push thyroid
Extremely large or small input values in the Thyroid Function may push thyroid function calculations beyond typical operating ranges. While mathematically valid, results from extreme inputs may not reflect realistic thyroid function scenarios and should be interpreted cautiously. In professional thyroid function settings, extreme values often indicate measurement errors, unusual conditions, or edge cases meriting additional analysis. Use sensitivity analysis to understand how results change across plausible input ranges rather than relying on single extreme-case calculations.
Extremely large or small input values in the Thyroid Function may push thyroid
Extremely large or small input values in the Thyroid Function may push thyroid function calculations beyond typical operating ranges. While mathematically valid, results from extreme inputs may not reflect realistic thyroid function scenarios and should be interpreted cautiously. In professional thyroid function settings, extreme values often indicate measurement errors, unusual conditions, or edge cases meriting additional analysis. Use sensitivity analysis to understand how results change across plausible input ranges rather than relying on single extreme-case calculations.
| TSH | FT4 | FT3 | Diagnosis | Common Cause |
|---|---|---|---|---|
| High (>4.0) | Low (<10) | Low/normal | Overt hypothyroidism | Hashimoto, post-RAI, post-thyroidectomy |
| High (>4.0) | Normal | Normal | Subclinical hypothyroidism | Early Hashimoto, iodine deficiency |
| Low (<0.4) | High (>20) | High (>6) | Overt hyperthyroidism | Graves disease, toxic adenoma |
| Low (<0.4) | Normal | Normal | Subclinical hyperthyroidism | Excess levothyroxine, early Graves |
| Low/normal | Low (<10) | Low/normal | Central hypothyroidism | Pituitary/hypothalamic disease |
| Normal | Normal | Normal | Euthyroid | No thyroid dysfunction |
Why is TSH measured first rather than FT4?
TSH is the most sensitive indicator of thyroid status because it is amplified by the logarithmic pituitary response to small changes in FT4. A 2-fold change in FT4 produces a 100-fold change in TSH. Therefore, TSH detects subtle thyroid dysfunction much earlier than FT4 or FT3, making it the superior first-line screening test.
What is the normal TSH range?
Most laboratories use a reference range of approximately 0.4-4.0 mU/L for TSH, derived from a population of healthy adults without thyroid disease. However, debate exists about whether the upper limit should be lowered to 2.5 mU/L, particularly in pregnancy and when treatment thresholds are being considered. Reference ranges vary slightly between laboratories and assay platforms.
What is sick euthyroid syndrome?
Sick euthyroid syndrome (non-thyroidal illness syndrome) occurs during acute or critical illness when thyroid hormone levels fall — typically T3 first, then T4, and TSH may be low, normal, or transiently elevated during recovery. This represents an adaptive response and should not be treated with thyroid hormones. Thyroid function tests should be repeated after recovery from the acute illness.
Can biotin supplements affect thyroid tests?
Yes, significantly. High-dose biotin (>5 mg/day) interferes with many immunoassays based on streptavidin-biotin technology, typically causing falsely low TSH and falsely elevated FT4 and FT3. Patients should stop biotin supplementation for at least 2-3 days before thyroid function testing. This is particularly important in the context of thyroid function calculations, where accuracy directly impacts decision-making. Professionals across multiple industries rely on precise thyroid function computations to validate assumptions, optimize processes, and ensure compliance with applicable standards. Understanding the underlying methodology helps users interpret results correctly and identify when additional analysis may be warranted.
What is the difference between total and free thyroid hormones?
Most T4 and T3 in blood is bound to carrier proteins (thyroxine-binding globulin, albumin, transthyretin). Only the free (unbound) fraction is biologically active. Free T4 (FT4) and free T3 (FT3) measurements are less affected by changes in binding proteins caused by pregnancy, oestrogen therapy, or nephrotic syndrome, making them more reliable than total T4 and total T3.
Why is FT3 not routinely measured?
FT3 is not part of routine thyroid screening because it adds little diagnostic information when TSH and FT4 are available in most circumstances. FT3 is useful when T3 toxicosis is suspected (TSH suppressed, FT4 normal), in monitoring amiodarone-treated patients, and in assessing conversion of T4 to T3 in sick patients.
How is thyroid function affected by pregnancy?
Human chorionic gonadotropin (hCG) stimulates TSH receptors, causing TSH to fall in the first trimester (gestational TSH suppression). Total T4 rises due to oestrogen-induced increases in thyroxine-binding globulin. Trimester-specific reference ranges for TSH must be used in pregnancy: approximately 0.1-2.5 mU/L in the first trimester. This is particularly important in the context of thyroid function calculations, where accuracy directly impacts decision-making. Professionals across multiple industries rely on precise thyroid function computations to validate assumptions, optimize processes, and ensure compliance with applicable standards. Understanding the underlying methodology helps users interpret results correctly and identify when additional analysis may be warranted.
Can thyroid function tests be normal in thyroid disease?
Yes, in central hypothyroidism the TSH may be inappropriately normal or low despite a low FT4. Also in early Hashimoto thyroiditis before significant gland destruction, and in treated patients on levothyroxine who are biochemically euthyroid despite having autoimmune disease. This is particularly important in the context of thyroid function calculations, where accuracy directly impacts decision-making. Professionals across multiple industries rely on precise thyroid function computations to validate assumptions, optimize processes, and ensure compliance with applicable standards. Understanding the underlying methodology helps users interpret results correctly and identify when additional analysis may be warranted.
Pro Tip
In any patient with a pituitary condition or hypothalamic disease, always measure FT4 alongside TSH. A TSH in the 'normal' range in this context does not exclude hypothyroidism — the pituitary cannot generate an appropriate TSH response. FT4 is the definitive test.
Did you know?
TSH is measured in milli-international units per litre, a unit that reflects extraordinarily tiny concentrations. The entire TSH content in a normal person's bloodstream at any given moment would fit comfortably in a few billionths of a gram — yet it controls every aspect of the thyroid gland's function.
References
- ›Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008
- ›American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism 2016
- ›Alexander EK et al. 2017 ATA Guidelines on Thyroid Disease During Pregnancy and Postpartum
- ›Jonklaas J et al. Guidelines for the Treatment of Hypothyroidism (ATA 2014)
- ›NICE Guideline NG145 — Thyroid Disease: Assessment and Management 2019